07 Nov2019
06 Nov2019
Variantyx Launches Its Whole Genome Sequencing (WGS)-Based In-Silico Panel Program at National Society of Genetic Counselors Annual Conference
FRAMINGHAM, Mass.–(BUSINESS WIRE)–Variantyx today announced the launch of its in-silico panel program which is an extension of its Genomic Unity™ whole genome sequencing (WGS)-based testing service. Available to clinicians since 2017, Genomic Unity™ has been instrumental in resolving many complex patient cases. It pairs the patient’s complete DNA sequence with proprietary data analysis algorithms to detect genome-wide small sequence changes, structural variants, mitochondrial variants and tandem repeat expansions – all within a single assay.
05 Nov2019
SQZ Biotech to Present First Time Data Demonstrating Potential of Company’s Second Novel Cell Therapy Approach in Oncology – Activating Antigen Carriers (AACs)
Preclinical data demonstrate SQZ AACs ability to prime antigen-specific T cell responses and drive tumor reduction in vivo
SQZ to also present additional preclinical data on company’s first oncology approach with SQZPBMC-HPV
WATERTOWN, Mass., Nov. 5, 2019 — SQZ Biotechnologies (SQZ), a clinical stage cell therapy company developing innovative treatments for multiple therapeutic areas, today announced the first data highlighting the potential of the company’s activating antigen carrier (AAC) immunotherapy program for oncology indications. The findings will be detailed in a poster presentation at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting. SQZ AACs are part of SQZ’s immune-oncology pipeline, which also includes SQZ Antigen Presenting Cells (APCs).
22 Oct2019
SQZ Biotech Announces Clearance of US IND Application for First Clinical Trial
First program advancing into the clinic through the SQZ-Roche collaboration in APCs for oncology
WATERTOWN, Mass., Oct. 22, 2019 (GLOBE NEWSWIRE) — SQZ Biotechnologies (SQZ), a cell therapy company developing innovative treatments for multiple therapeutic areas, today announced that the company’s Investigational New Drug (IND) application for SQZ-PBMC-HPV, a novel cellular immunotherapy of antigen presenting cells (APCs) has been cleared after submission to the U.S. Food and Drug Administration (FDA).
21 Oct2019